Positive Media Coverage Extremely Likely to Impact Bio-Rad Laboratories (BIO) Stock Price

News headlines about Bio-Rad Laboratories (NYSE:BIO) have been trending positive this week, according to InfoTrie. The research group identifies negative and positive media coverage by analyzing more than 6,000 blog and news sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Bio-Rad Laboratories earned a coverage optimism score of 2.29 on their scale. InfoTrie also gave media coverage about the medical research company an news buzz score of 10 out of 10, meaning that recent media coverage is extremely likely to have an impact on the stock’s share price in the next several days.

These are some of the headlines that may have effected Bio-Rad Laboratories’ analysis:

Shares of BIO stock opened at $277.45 on Tuesday. The company has a quick ratio of 3.16, a current ratio of 4.49 and a debt-to-equity ratio of 0.09. Bio-Rad Laboratories has a 12-month low of $231.00 and a 12-month high of $345.15. The firm has a market cap of $8.22 billion, a PE ratio of 67.67, a P/E/G ratio of 3.34 and a beta of 1.09.

Bio-Rad Laboratories (NYSE:BIO) last issued its quarterly earnings data on Thursday, November 1st. The medical research company reported $0.91 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $1.16 by ($0.25). The company had revenue of $545.10 million for the quarter, compared to the consensus estimate of $541.23 million. Bio-Rad Laboratories had a return on equity of 3.72% and a net margin of 55.13%. The firm’s revenue was up 2.1% on a year-over-year basis. During the same period in the prior year, the company earned $0.91 EPS. On average, research analysts anticipate that Bio-Rad Laboratories will post 5.47 EPS for the current fiscal year.

Several equities research analysts have commented on BIO shares. Barclays assumed coverage on shares of Bio-Rad Laboratories in a research note on Wednesday, September 5th. They issued an “equal weight” rating and a $345.00 target price for the company. Jefferies Financial Group reissued a “buy” rating and set a $420.00 price objective on shares of Bio-Rad Laboratories in a research report on Monday, September 24th. Goldman Sachs Group assumed coverage on shares of Bio-Rad Laboratories in a research report on Wednesday, October 17th. They set a “buy” rating and a $350.00 price objective for the company. Morgan Stanley assumed coverage on shares of Bio-Rad Laboratories in a research report on Thursday, September 20th. They set an “equal weight” rating and a $335.00 price objective for the company. Finally, Zacks Investment Research downgraded shares of Bio-Rad Laboratories from a “buy” rating to a “hold” rating in a research report on Monday, August 13th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and five have issued a buy rating to the company’s stock. Bio-Rad Laboratories has an average rating of “Hold” and an average target price of $338.43.

COPYRIGHT VIOLATION WARNING: “Positive Media Coverage Extremely Likely to Impact Bio-Rad Laboratories (BIO) Stock Price” was originally published by Community Financial News and is the sole property of of Community Financial News. If you are accessing this news story on another domain, it was illegally stolen and reposted in violation of U.S. and international trademark and copyright law. The original version of this news story can be read at https://www.com-unik.info/2018/12/04/positive-media-coverage-extremely-likely-to-impact-bio-rad-laboratories-bio-stock-price.html.

Bio-Rad Laboratories Company Profile

Bio-Rad Laboratories, Inc develops, manufactures, and markets products and solutions for the life science research and clinical diagnostic markets in Europe, the Pacific Rim, the United States, and internationally. The company offers products and systems to separate complex chemical and biological materials, as well as to identify, analyze, and purify components.

Further Reading: Dollar Cost Averaging

Insider Buying and Selling by Quarter for Bio-Rad Laboratories (NYSE:BIO)

Receive News & Ratings for Bio-Rad Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Rad Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit